While there were outliers, Marston said a major chunk of the investments are concentrated in a few key hubs: Pennsylvania and ...

Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.

Oracle patches roughly 230 unique CVEs across more than 30 products with its first Critical Patch Update (CPU) released in ...

Infosys (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, delivered ...

Alexandria Real Estate Equities has offloaded its life sciences office building in Long Island City, Queens, at a $40.5 million discount from its 2018 purchase price, according to city records made ...

Bank OZK has found a buyer for a nine-figure construction loan backing a mostly empty life sciences campus in Southern California. The lender sold a $265 million loan tied to Pacific Center, a 500,000 ...

CAMBRIDGE, Mass.—Jeremy Liew, 31 years old, moved to Boston from New Jersey in 2018 to study for a Ph.D. in chemistry and, he hoped, a career in the city’s bustling biotech industry. But after earning ...

Everyday life is full of small behaviors we treat as moral choices, scientific truths, or acts of civic virtue—often without much reflection. From abandoned shopping carts to climate guilt over pet ...

Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...

Power Moves is a recurring series where we chart the comings and goings of talent across the region. Got a new hire, gig or promotion? Email us at philly@technical.ly. Philly companies and ...

Healthcare is high stakes. When people go to the hospital, it’s often during some of the most difficult moments of their lives. When someone’s health is on the line — even during a routine visit — ...

Over the past four years, private equity (PE) firms that invested in life science assets have faced a difficult reality. While many investors still debate whether some sectors of the market are in a ...